Recombinant Human CDKN1B

Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Recombinant Human CDKN1B
category
Proteins and Peptides
provider
FineTest
reference
P1012
tested applications
Western Blot, ELISA

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Host
E.Coli
Reactivity
Human
Assay Data
Centrifuge the vial before opening, reconstitute in sterile distilled water to a concentration of 0.1-1 mg/ml by gently pipetting 2-3 times, don't vortex.
Recommended Dilution
¥
Isotype
¥
Clone ID
¥
Observed MW
32 kDa
Expression
90-197
Purity
Greater than 90% as determined by SDS-PAGE.
Size 1
50μg
Size 2
200μg
Size 3
1mg
Form
Lyophilized powder
Tested Applications
Western Blot, ELISA
Buffer
Lyophilized from a 0.2 μm filtered solution in 10 mM Hepes, 500 mM NaCl with 5% trehalose, pH 7.4.
Availability
7 days
Storage
The lyophilized protein is stable at -20 °C for up to 1 year. After reconstitution, the protein solution is stable at -20 to -80 °C for 3 months or 1 week at 2 to 8 °C under sterile conditions. For extended storage, it is recommended to further dilute in working aliquots, avoid repeated freeze/thaw cycle.
UniProt ID
P46527
Alias
AA408329, AI843786, Cdki1b, CDKN 1B, CDKN 4, CDKN1B, CDKN4, CDN1B_HUMAN, Cyclin Dependent Kinase Inhibitor 1B, Cyclin dependent kinase inhibitor p27, Cyclin-dependent kinase inhibitor 1B, Cyclin-dependent kinase inhibitor 1B (p27, Kip1), Cyclin-dependent kinase inhibitor p27
Background
Protein CDKN1B
Status
RUO
Note
Tag : N-terminal His-IF2DI Tag

Related Products

EH4327

Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit

Ver Producto
EM0914

Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit

Ver Producto
FNab06068

CDKN1B antibody

CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.

Ver Producto